RCAG
DRNA

Rehmann Capital Advisory Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Rehmann Capital Advisory Group’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$447K Sell
31,125
-30,863
-50% -$441K 0.05% 180
2019
Q2 		$976K Buy
+61,988
New +$843K 0.12% 136

Other funds holding DRNA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rehmann Capital Advisory Group's DRNA Position: Q3 2019 in Review

Rehmann Capital Advisory Group reduced its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 50% in Q3 2019, selling an estimated $441K and leaving 31,125 shares worth $447K. The position accounts for 0.05% of the portfolio, ranked #180.

Rehmann Capital Advisory Group first reported a position in DRNA in Q2 2019 and has held it in 2 quarters since. The position peaked at $976K in Q2 2019. 112 funds tracked by Wall St. Rank hold DRNA as of Q3 2019.

  • Rehmann Capital Advisory Group held 31,125 shares of Dicerna Pharmaceuticals, Inc. worth $447K as of Q3 2019.
  • Rehmann Capital Advisory Group sold 30,863 Dicerna Pharmaceuticals, Inc. shares in Q3 2019, an estimated $441K.
  • Dicerna Pharmaceuticals, Inc. made up 0.05% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #180 holding.
  • Rehmann Capital Advisory Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2019 and has held it in 2 quarters since.
  • Rehmann Capital Advisory Group's Dicerna Pharmaceuticals, Inc. position peaked at $976K in Q2 2019.
  • 112 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.